Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for Retinopathy of Prematurity | Kisho | Kisho

Back to Retinopathy of Prematurity

Retinopathy of Prematurity — NIH Grants & Funding

Active and recent NIH-funded research on Retinopathy of Prematurity. Data from NIH RePORTER, last 36 months.

MONDO:0006952

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

Retinopathy of Prematurity has a robust NIH research funding landscape with 38 funded grants and $38.2M in total funding over the period.

38funded grants from NIH

Portfolio: $13.1MCumulative: $38.2M23 active15 completed41 PIs26 institutions

-9% YoY(FY2024 vs FY2025)

1 new grant started in the last 12 months.

By Research Theme

Basic Science

Translational

Clinical

Biomarker / Dx

Epi / Nat. History

Medical Device

1 additional grant classified as “Other” (multi-disciplinary, infrastructure, etc.).

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$8.5M

FY22

$11.3M

FY23

$8.9M

FY24

$8.2M

FY25

$1.3M

FY26

By Funding Mechanism

R01

R21

R56

F31

K08

R00

Adjacent Research(27 grants)

These grants mention Retinopathy of Prematurity as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(27)

OtherR44Active

First-in-class TREM-1 inhibitors for neovascular retinal diseases

Sigalov, Alexander·SIGNABLOK, INC.·WORCESTER, MA

$830,491 (FY2025)

NIH RePORTER

OtherR01Active

Mechanisms of Oxygen Toxicity

Jain, Isha·J. DAVID GLADSTONE INSTITUTES·SAN FRANCISCO, CA

$731,827 (FY2025)

NIH RePORTER

OtherR01Active

Advancing visible-light OCT in oxygen-induced retinopathy

Campbell, John et al.·OREGON HEALTH & SCIENCE UNIVERSITY·PORTLAND, OR

$691,728 (FY2025)

NIH RePORTER

OtherP30Completed

NEI Center Core Grant for Vision Research

ANAND-APTE, BELA·CLEVELAND CLINIC LERNER COM-CWRU·CLEVELAND, OH

$644,002 (FY2025)

NIH RePORTER

OtherR01Active

Endothelial Rap1 restricts inflammation in the retina

Chrzanowska, Magdalena et al.·VERSITI BLOOD HEALTH, INC.·MILWAUKEE, WI

$570,083 (FY2025)

NIH RePORTER

OtherR01Active

The role of heme in retinal vascular development and disease

Antonetti, David et al.·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$512,042 (FY2025)

NIH RePORTER

OtherR01Active

G protein-coupled receptor regulation of transcriptional mechanisms in the retinal vasculature.

Hla, Timothy·BOSTON CHILDREN'S HOSPITAL·BOSTON, MA

$475,344 (FY2025)

NIH RePORTER

OtherR01Active

Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models

Junge, Harald·UNIVERSITY OF MINNESOTA·MINNEAPOLIS, MN

$453,631 (FY2026)

NIH RePORTER

OtherR01Completed

Neural Retina-Specific Bim Expression and Hyperoxia Sensitivity of the Developing Retinal Vasculature

Zaitoun, Ismail·UNIVERSITY OF WISCONSIN-MADISON·MADISON, WI

$425,988 (FY2025)

NIH RePORTER

OtherR01Active

Innate immunomodulation of retinal neovascularization

Gnanaguru, Gopalan·TUFTS MEDICAL CENTER·BOSTON, MA

$391,912 (FY2025)

NIH RePORTER

Kisho

Retinopathy of Prematurity — NIH Grants & Funding

Funding Landscape

By Research Theme

Funding by Fiscal Year

By Funding Mechanism

Adjacent Research(27 grants)

Other(27)

First-in-class TREM-1 inhibitors for neovascular retinal diseases

Mechanisms of Oxygen Toxicity

Advancing visible-light OCT in oxygen-induced retinopathy

NEI Center Core Grant for Vision Research

Endothelial Rap1 restricts inflammation in the retina

The role of heme in retinal vascular development and disease

G protein-coupled receptor regulation of transcriptional mechanisms in the retinal vasculature.

Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models

Neural Retina-Specific Bim Expression and Hyperoxia Sensitivity of the Developing Retinal Vasculature

Innate immunomodulation of retinal neovascularization

Top Funded Institutions

Top Principal Investigators